Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research note issued on Tuesday.
Cellectar Biosciences Stock Down 0.5 %
Shares of NASDAQ CLRB opened at $2.10 on Tuesday. The business’s 50 day moving average is $2.19 and its two-hundred day moving average is $2.89. Cellectar Biosciences has a 52-week low of $1.82 and a 52-week high of $4.45. The firm has a market cap of $75.28 million, a price-to-earnings ratio of -0.68 and a beta of 0.99.
Hedge Funds Weigh In On Cellectar Biosciences
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Rosalind Advisors Inc. boosted its stake in shares of Cellectar Biosciences by 335.4% in the second quarter. Rosalind Advisors Inc. now owns 2,705,616 shares of the biopharmaceutical company’s stock valued at $6,764,000 after purchasing an additional 2,084,138 shares during the period. ADAR1 Capital Management LLC purchased a new position in Cellectar Biosciences in the 4th quarter valued at approximately $3,817,000. AIGH Capital Management LLC grew its stake in shares of Cellectar Biosciences by 182.7% in the fourth quarter. AIGH Capital Management LLC now owns 1,915,220 shares of the biopharmaceutical company’s stock worth $5,305,000 after acquiring an additional 1,237,709 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Cellectar Biosciences by 146.7% during the first quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock worth $4,741,000 after acquiring an additional 708,191 shares during the period. Finally, XTX Topco Ltd raised its stake in shares of Cellectar Biosciences by 432.4% in the second quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 51,413 shares in the last quarter. 16.41% of the stock is currently owned by hedge funds and other institutional investors.
Cellectar Biosciences Company Profile
Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
See Also
- Five stocks we like better than Cellectar Biosciences
- How to Calculate Stock Profit
- How Much Can You Make in Stocks in One Month?
- How to Use the MarketBeat Dividend Calculator
- This Is the Top Large-Cap Stock Insiders Are Buying
- Find and Profitably Trade Stocks at 52-Week Lows
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.